LBA:01:19 Real-world feasibility of treat-to-target recommendations in systemic lupus erythematosus: analysis of 321 patients from an academic lupus clinic

Lupus Science & Medicine 2026 Open access

Read full text
Authors: Maria João Cadório, José A.P. da Silva, Luís Inês
DOI: 10.1136/lupus-2026-el.418
Cited by: 0

Abstract

Objectives The 2023 EULAR and 2025 ACR SLE recommendations endorse a treat-to-target (T2T) strategy aiming for sustained remission or low disease activity (LDA), with prednisone (PDN)

Fields of Study & Subjects

Systemic Lupus Erythematosus Research Systemic Sclerosis and Related Diseases Autoimmune and Inflammatory Disorders Research

Publication details

Journal / source
Lupus Science & Medicine
Pages
A351.2–A352
Publication date
1 March 2026
Language
EN